Menu

Close

Sign InSign Out

Materials

Co-pay Cards & Patient Savings Offers

Request Samples

Hospital Products

Vaccines

Pfizer Oncology Together

Pfizer RxPathways

Events

Materials

Videos

Menu

Close

Efficacy

Phase III Study Primary Endpoints

Success in ISGA: Clear or ​​​​​​​almost clear

Study Design

Phase III Study Secondary Endpoints

ISGA clear or almost clear

Time to ISGA success

Phase III Study: Other Endpoints

Pruritus

Quality of life assessments

Infant Study: Exploratory efficacy Endpoints

ISGA clear or almost clear

%BSA, EASI & POEM

Safety Data

Phase III Study Adverse Reactions*

Pivotal trial & 48-week extension study
Adverse Reactions

Open-Label Safety Extension Study*

Open-Label Safety Extension Study Rescue ​​​​​​​Therapy Endpoint

Study design

Infant Safety Study**

Adverse Reactions

Study design and Demographics

Savings & Support

Events

Materials

Videos

Copay Cards

Cost and Coverage

  • Prescribing Information
  • Patient Information
  • Patient Site
    •

    EUCRISA (crisaborole): A steroid-free option

    For the treatment of mild-to-moderate atopic dermatitis in patients 3 months and older

    Copay Cards

    *Eligible patients pay as little as $10

    *Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,880. This card will be accepted only at participating pharmacies. This card is not health insurance.

    Download Copay Cards

    ** This is an optional area where footnotes can live.

    Order Samples

    Register or sign in to check availability and request samples

    Order now

    ** This is an optional area where footnotes can live.

    Infant Safety Study in patients 3 to <24 months of age

    Learn more about a 28-day, single-arm, open-label safety study in 3 to <24 month old patients4

    Learn more

    ** This is an optional area where footnotes can live.

    “Sometimes I don’t even want to look at my own skin”

    Nana is a dancer who has had mild-to-moderate atopic dermatitis for more than 30 years

    View Nana's story

    Efficacy

    EUCRISA has proven efficacy across all pivotal trial primary and secondary endpoints in patients aged 2 years and up1,2

    Learn more

    ** This is an optional area where footnotes can live.

    Safety Data

    Learn more about the safety data of EUCRISA from the 4-week pivotal trials and open-label safety extension study1,3

    View safety data

    ** This is an optional area where footnotes can live.

    Dosing

    EUCRISA can be applied to the skin anywhere on the face and body1

    For topical use only. Not for ophthalmic, oral or intravaginal use

    Understand more

    ** This is an optional area where footnotes can live.

    References
    1. EUCRISA® (crisaborole) Full Prescribing Information. April 2020.
       
    2. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e4.
       
    3. Eichenfield LF, Tom WL, Berger TJ, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1)116-132.
       
    4. Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020. 21:275-284.

    Contraindications

    EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

    Warnings and Precautions

    Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

    Adverse Reactions

    The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.

    Please see Full Prescribing Information and Patient Information

    EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    INDICATION

    EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.

    Please see full Prescribing Information.

    OK. We'll need you to sign in before we can determine if you are aligned with a sales  representative. 

    If you select 'Yes', you will be required to enter your username and password in the sign-in form  that will appear over this window.  

    Would you like to sign in now?